<DOC>
	<DOCNO>NCT00666991</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics preliminary efficacy intraperitoneally administer suspension nanoparticulate paclitaxel patient refractory malignancy principally confine peritoneal cavity .</brief_summary>
	<brief_title>Pharmacokinetic , Safety Efficacy Study Nanoparticle Paclitaxel Patients With Peritoneal Cancers</brief_title>
	<detailed_description>This open-label , Phase 1 , dose-escalation study evaluate safety , pharmacokinetics preliminary efficacy intraperitoneally administer suspension nanoparticle paclitaxel ( Nanotax ) patient refractory malignancy principally confine peritoneal cavity . Nanotax administered via intraperitoneal infusion every 28 day ( equal one treatment cycle ) , continue treatment schedule disease progression unacceptable toxicity experience . This study treat one patient per predefined dose level one patient experience dose limit toxicity ( DLT ) one patient Grade 2 high non-hematological toxicity Grade 3 high hematological toxicity first cycle treatment . At time , two additional patient treat dose level . If 2 additional patient experience DLT , next cohort three patient treat next high dose level . If 2/3 3/3 patient experience DLT next cohort three patient enrol next low dose level . If 1/3 patient experience DLT , next cohort three patient enrol dose level . If 0/3 patient experience DLT , next cohort three patient enrol next high dose level . If 2 ( ) /6 patient give level experience DLT , maximum tolerate dose exceed another cohort three patient treat next low dose level . The protocol treat high dose level 275 mg/m2 . Adverse event data collect throughout study . Peritoneal fluid blood sample collect prior Nanotax administration 14 day follow infusion Cycle 1 Cycle 2 . Evaluation tumor response use RECIST criterion conduct follow treatment cycle .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients must least 18 year age . Patients must histologic cytologic diagnosis carcinoma predominantly confine peritoneal cavity . Patients must fail potentially curative therapy systemic treatment option available extraperitoneal disease . Patients ovarian cancer platinum sensitive must fail primary least one salvage regimen . Patients may undergo surgical debulking prior entry trial . At least 28 day must elapse since completion previous chemotherapy treatment receive prior registration study . Patients may receive prior abdominal surgery great 2 week prior registration . Patients must recover effect surgical procedure . Patients must Zubrod Performance Status 0 2 . Patients must pretreatment granulocyte count great equal 1,500/microliter platelet count great equal 100,000/microliter obtain within 14 day prior registration . Patients must adequate renal function document serum creatinine less equal 1.5 time institutional upper limit normal obtain within 14 day prior registration . Patients must adequate hepatic function document bilirubin less equal 2 time institutional upper limit normal SGOT le 5 time institutional upper limit normal obtain within 14 day prior registration . Patients hepatobiliary stent eligible trial bilirubin meet parameter . There plan patient receive concomitant radiation therapy , hormonal therapy , chemotherapy tumor protocol . Patients active inflammatory bowel disease chronic diarrhea Patients uncontrolled hypertension , unstable angina , symptomatic congestive heart failure , myocardial infarction within previous 6 month serious uncontrolled cardiac arrhythmia Patients active infection require systemic therapy Pregnant nursing woman Patients Grade 2 great sensory neuropathy ( NCI Common Toxicity Criteria ) time study registration Patients take concomitant medication demonstrate inhibit induce CYP3A4 CYP2C8 Patients preexist condition prohibit use intravenous dexamethasone recommend dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>Mullerian tumor</keyword>
	<keyword>peritoneal cavity carcinoma</keyword>
	<keyword>gastrointestinal tract tumor</keyword>
	<keyword>GI tract tumor</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>colon cancer</keyword>
</DOC>